DK0961612T3 - Protein-stabiliserede-farmakologisk-aktive-midler og deres anvendelse - Google Patents

Protein-stabiliserede-farmakologisk-aktive-midler og deres anvendelse

Info

Publication number
DK0961612T3
DK0961612T3 DK97944429T DK97944429T DK0961612T3 DK 0961612 T3 DK0961612 T3 DK 0961612T3 DK 97944429 T DK97944429 T DK 97944429T DK 97944429 T DK97944429 T DK 97944429T DK 0961612 T3 DK0961612 T3 DK 0961612T3
Authority
DK
Denmark
Prior art keywords
protein
pharmacologically active
active agents
absence
active agent
Prior art date
Application number
DK97944429T
Other languages
English (en)
Other versions
DK0961612T4 (da
Inventor
Neil P Desai
Tianli Zheng
Patrick Soon-Shiong
Shlomo Magdassi
Chunlin Tao
Andrew Yang
Leslie Louie
Zhiwen Yao
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24895164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0961612(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Application granted granted Critical
Publication of DK0961612T3 publication Critical patent/DK0961612T3/da
Publication of DK0961612T4 publication Critical patent/DK0961612T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pediatric Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK97944429.6T 1996-10-01 1997-09-24 Protein-stabiliserede, farmakologisk aktive midler og deres anvendelse DK0961612T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/720,756 US5916596A (en) 1993-02-22 1996-10-01 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PCT/US1997/017157 WO1998014174A1 (en) 1996-10-01 1997-09-24 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Publications (2)

Publication Number Publication Date
DK0961612T3 true DK0961612T3 (da) 2009-06-15
DK0961612T4 DK0961612T4 (da) 2012-10-08

Family

ID=24895164

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97944429.6T DK0961612T4 (da) 1996-10-01 1997-09-24 Protein-stabiliserede, farmakologisk aktive midler og deres anvendelse

Country Status (19)

Country Link
US (1) US5916596A (da)
EP (3) EP1944019B1 (da)
JP (2) JP4837809B2 (da)
CN (2) CN1515244B (da)
AT (1) ATE427739T1 (da)
AU (1) AU718753B2 (da)
BR (2) BRPI9715297B8 (da)
CA (2) CA2267498C (da)
DE (2) DE69739348D1 (da)
DK (1) DK0961612T4 (da)
ES (2) ES2609853T3 (da)
FR (1) FR09C0050I2 (da)
HK (1) HK1024866A1 (da)
LU (1) LU91613I2 (da)
NL (1) NL300417I1 (da)
NO (1) NO328689B1 (da)
NZ (1) NZ335133A (da)
PT (1) PT961612E (da)
WO (1) WO1998014174A1 (da)

Families Citing this family (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
DK0693924T4 (da) * 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20070122465A1 (en) * 1993-02-22 2007-05-31 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2294981C (en) * 1997-06-27 2012-04-03 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP3266450A1 (en) * 1997-06-27 2018-01-10 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP4272811B2 (ja) * 1997-09-05 2009-06-03 マルホ株式会社 関節内疾患治療用のナノカプセル製剤
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
US6884842B2 (en) 1997-10-14 2005-04-26 Alnis Biosciences, Inc. Molecular compounds having complementary surfaces to targets
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
CA2362338A1 (en) * 1998-07-30 2000-02-10 Human Rt. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
GB9820746D0 (en) † 1998-09-23 1998-11-18 Pharmax Limited Micronised pharmaceutical compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
AT406054B (de) * 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
DE19919769A1 (de) 1999-04-30 2000-11-02 Henkel Kgaa Verwendung nanoskaliger antimikrobieller Wirkstoffe in Körperdeodorantien
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
CA2371912C (en) * 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
EP1221968B1 (en) * 1999-10-13 2010-01-13 Novartis Vaccines and Diagnostics, Inc. Method of obtaining cellular immune responses from proteins
WO2001049268A1 (en) * 2000-01-05 2001-07-12 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
ATE432063T1 (de) * 2000-03-23 2009-06-15 Basf Catalysts Llc Verfahren zur herstellung von physiologisch aktiven substanzen enthaltenden dispersionen unter anwendung von hochdruck und hochscherkraft
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
AU2001291243A1 (en) 2000-09-27 2002-04-08 Verion Inc. Instant water dissolvable encapsulate and process
MXPA03002851A (es) * 2000-10-02 2003-07-14 Kimberly Clark Co Tintas con base de nanoparticula y los metodos para hacer las mismas.
BR0115260A (pt) 2000-11-09 2005-08-16 Neopharm Inc Complexos de sn-38 com lipìdeos e seus usos no tratamento de doenças
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
CA2440935A1 (en) * 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
AU2002245979A1 (en) * 2001-04-05 2002-10-21 Universite Laval Process for making protein delivery matrix and uses thereof
ES2286244T3 (es) * 2001-04-20 2007-12-01 The University Of British Columbia Sistemas de suministro de farmaco micelar para farmacos hirofobicos.
SG126676A1 (en) * 2001-05-09 2007-01-30 Nanomaterials Tech Pte Ltd Process for the controlled production of organic particles
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
US20040013698A1 (en) * 2001-07-09 2004-01-22 Aust Duncan T Method for preparing topical preparations containing skin protective agents with enhanced barrier properties
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US20040018250A1 (en) * 2001-07-11 2004-01-29 Ceccoli Joseph D. Methods for preparing high pressure/high shear dispersions containing waxes and other semi-solids and oils
WO2003013683A1 (en) * 2001-08-08 2003-02-20 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) * 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
IL160927A0 (en) * 2001-10-15 2004-08-31 Crititech Inc Compositions and methods for delivery of poorly water soluble drugs and method of treatment
US20040015519A1 (en) * 2001-10-15 2004-01-22 Yukitoshi Maeda Content delivery server and content delivery system having the same
PL210795B1 (pl) 2001-10-19 2012-03-30 Isotechnika Inc Sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (E), sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (Z), sposób stereoselektywnej syntezy izomeru (E) ISATX247, sposób stereoselektywnej syntezy izomeru (Z) ISATX247 i sposób wytwarzania mieszaniny izomerów ISATX247
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003037359A1 (fr) * 2001-10-29 2003-05-08 Chengdu Somo Namotechnology Co., Ltd. Nanoparticule de composants de medicaments insolubles et procede de production correspondant
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
ATE464880T1 (de) * 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2479665C (en) † 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2003224808A1 (en) * 2002-03-28 2003-10-13 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
AU2003263024A1 (en) * 2002-04-23 2003-11-10 Christopher Mcconville Process of forming and modifying particles and compositions produced thereby
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP2324866B1 (en) * 2002-07-12 2014-06-18 Cook Medical Technologies LLC Angioplasty balloons drug-coated in an expanded condition
DK1521572T3 (da) * 2002-07-15 2009-05-04 Alcon Inc Biologisk nedbrydelig film til indförsel af öjenlægemiddel
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
ATE442130T1 (de) 2002-08-12 2009-09-15 Bend Res Inc Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7090868B2 (en) * 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
AU2002342808A1 (en) * 2002-10-09 2004-05-04 Unibioscreen S.A. Extract with anti-tumor and anti-poisonous activity
EP1556011A1 (en) * 2002-10-28 2005-07-27 Polymerix Corporation Therapeutic compositions
WO2004098570A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
WO2004045494A2 (en) * 2002-11-20 2004-06-03 Bar-Ilan University Biological glue based on thrombin-conjugated nanoparticles
RU2361615C2 (ru) * 2002-12-09 2009-07-20 Абраксис Байосайенс, Ллс. Композиции и способы доставки фармакологических агентов
BR0317134A (pt) * 2002-12-09 2005-11-22 American Bioscience Inc Composições e métodos de liberação de agentes farmacológicos
JP2006524632A (ja) * 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド 組成物及び薬物送達方法
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US6780896B2 (en) * 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
DE60311958T2 (de) * 2003-02-03 2007-11-08 Polaschegg, Hans-Dietrich, Dr. Zusammensetzung zur Prävention von Infektionen durch subkutane Prothesen
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
WO2004080396A2 (en) * 2003-03-07 2004-09-23 The University Of Texas Md Anderson Cancer Center Liposomal curcumin for treatment of cancer
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
JP2007507432A (ja) * 2003-10-02 2007-03-29 セムバイオシス ジェネティクス インコーポレイテッド 活性成分を含む油体を調製するための方法
US7837663B2 (en) * 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
US7438875B2 (en) * 2003-10-16 2008-10-21 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified silica particles
US7879350B2 (en) * 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7700612B2 (en) * 2003-12-23 2010-04-20 Abraxis Bioscience, Llc Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
US20070185217A1 (en) * 2003-12-23 2007-08-09 Abraxis Bioscience, Inc. Propofol analogs, process for their preparation, and methods of use
EP1701718A4 (en) * 2003-12-23 2009-06-24 Abraxis Bioscience Llc SUBSTITUTED MELATONIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD OF ADMINISTRATION
US20050186230A1 (en) * 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20080103213A1 (en) * 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
CA2562731A1 (en) * 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of fentanyl-based agents
CA2469339A1 (en) * 2004-06-07 2005-12-07 Bernard Charles Sherman Sustained release propafenone hydrochloride capsules
EP2305642A3 (en) 2004-06-23 2011-12-14 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100578382B1 (ko) 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
BRPI0519088A2 (pt) * 2004-12-15 2008-12-23 Elan Pharma Int Ltd formulaÇÕes de tacrolimo nanoparticuladas
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8026275B2 (en) 2005-02-18 2011-09-27 Abraxis Bioscience, Llc Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
KR101914254B1 (ko) 2005-02-18 2018-11-02 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
US8415388B2 (en) 2005-02-22 2013-04-09 Savvipharm Inc. Pharmaceutical compositions containing paclitaxel orotate
BRPI0606282A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições injetáveis de compostos imunossupressores em nanopartìculas
US7722581B2 (en) * 2005-04-11 2010-05-25 Gholam A. Peyman Crystalline lens drug delivery
US20060229585A1 (en) * 2005-04-11 2006-10-12 Minu, L.L.C. Drug delivery to the crystalline lens and other ocular structures
BRPI0607537A2 (pt) 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
CA2604907A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
EP2404594B1 (en) * 2005-08-31 2017-12-20 Abraxis BioScience, LLC Compositions comprising docetaxel with increased stability
JP5116108B2 (ja) * 2005-09-09 2013-01-09 トクレ チョン， 抗癌剤の伝達体用水溶性キトサンナノ粒子及びその製造方法
US20070098802A1 (en) * 2005-10-31 2007-05-03 Isaac Farr Organic nanoparticles and associated methods
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
CA2631714C (en) 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
KR20080091158A (ko) 2005-12-28 2008-10-09 다브르 파마 리미티드 나노 입자형 약제학적 조성물용으로 유용한, 생혼화성이고비생분해성이며 비독성인 중합체
SE529040C2 (sv) 2006-01-18 2007-04-17 Bows Pharmaceuticals Ag Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
JP4974533B2 (ja) * 2006-01-30 2012-07-11 富士フイルム株式会社 ジスルフィド架橋したタンパク質ナノ粒子
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US7458953B2 (en) * 2006-06-20 2008-12-02 Gholam A. Peyman Ocular drainage device
US8728527B2 (en) * 2006-07-24 2014-05-20 Luminus Biosciences, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
AU2007288338B2 (en) 2006-08-21 2012-05-03 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
AU2007290490B2 (en) * 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2008030557A2 (en) * 2006-09-08 2008-03-13 Johns Hopkins University Compositions and methods for enhancing transport through mucus
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
US20110021592A1 (en) * 2006-09-14 2011-01-27 Shlomo Magdassi Organic nanoparticles obtained from microemulsions by solvent evaporation
JP2010504359A (ja) 2006-09-20 2010-02-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法
JP5099545B2 (ja) * 2006-10-17 2012-12-19 公立大学法人大阪府立大学 化合物の溶解補助剤とそれを含む組成物
PT2091919E (pt) * 2006-11-15 2011-09-05 Abraxis Bioscience Llc Derivados de análogos de hidroquinona de geldamicina substituídos por 18-amino que apresentam atividade citotóxica para o tratamento de cancro.
US7799954B2 (en) * 2006-11-17 2010-09-21 Abraxis Bioscience, Llc Dicarbonyl derivatives and methods of use
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
AU2007333925B2 (en) * 2006-12-15 2013-10-31 Nantbio, Inc. Triazine derivatives and their therapeutical applications
DK2481402T3 (da) 2007-03-07 2018-08-06 Abraxis Bioscience Llc Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer
EP2146707A2 (en) 2007-05-03 2010-01-27 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
ES2435452T3 (es) * 2007-06-01 2013-12-19 Abraxis Bioscience, Llc Métodos y composiciones para tratar un cáncer recurrente
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
DK2244737T3 (da) 2008-01-22 2019-07-08 Univ Texas Flygtige anæstetiske sammensætninger omfattende ekstraktionsopløsningsmidler til regional anæstesi og/eller smertelindring
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
TW200942233A (en) * 2008-04-10 2009-10-16 Abraxis Bioscience Llc Compositions of hydrophobic taxane derivatives and uses thereof
US9126025B2 (en) * 2008-05-01 2015-09-08 Bayer Intellectual Property Gmbh Method of coating a folded catheter balloon
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
NZ593343A (en) 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
CA2755121A1 (en) 2009-03-13 2010-09-16 Neil P. Desai Combination therapy with thiocolchicine derivatives
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
ME03596B (me) 2009-04-15 2020-07-20 Abraxis Bioscience Llc Kompozicije nanočesтica bez priona i postupci povezani sa njima
AU2010258800B2 (en) 2009-06-09 2013-10-10 Nantbio, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
WO2010144394A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Benzyl substituted triazine derivatives and their therapeutical applications
WO2010144550A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
CN101653611B (zh) * 2009-07-23 2012-05-09 复旦大学 一种白蛋白-阿霉素纳米制剂及其制备方法和应用
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
UA110196C2 (uk) 2009-08-25 2015-12-10 Абраксіс Байосайєнс, Елелсі Комбінована терапія композиціями наночастинок таксану і інгібіторами хеджхог
US10350364B2 (en) 2009-11-11 2019-07-16 Windgap Medical, Inc. Portable Drug Mixing and Delivery Device and Associated Methods
US9211283B2 (en) 2009-12-11 2015-12-15 Biolitec Pharma Marketing Ltd Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
WO2011097149A2 (en) * 2010-02-03 2011-08-11 Oncbiomune, L.L.C. Taxane-and taxoid-protein compositions
ES2675212T3 (es) 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
DK2552415T3 (da) 2010-03-29 2016-11-28 Abraxis Bioscience Llc Fremgangsmåder til behandling af cancer
US20110262347A1 (en) 2010-04-08 2011-10-27 The Salk Institute For Biological Studies Methods and compositions for enhanced delivery of compounds
CN103221042B (zh) 2010-06-02 2016-02-10 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
CN103140225A (zh) 2010-06-04 2013-06-05 阿布拉科斯生物科学有限公司 治疗胰腺癌的方法
SG185798A1 (en) 2010-06-07 2013-01-30 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
CN103202812B (zh) * 2010-08-09 2015-10-28 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
CN103202813B (zh) * 2010-08-09 2015-09-30 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
KR101223484B1 (ko) 2010-10-05 2013-01-17 한국과학기술연구원 사람 혈청 알부민-ｓｉＲＮＡ 나노입자 전달체
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
RU2475247C2 (ru) * 2011-03-05 2013-02-20 Республика Северная Осетия-Алания "Всероссийское общество изобретателей и рационализаторов" ("ВОИР") Способ профилактики несостоятельности кишечного анастомоза
CN102133190A (zh) * 2011-03-16 2011-07-27 中国药科大学 一种转铁蛋白纳米粒及其制备方法和用途
CO6540157A1 (es) 2011-04-15 2012-10-16 Univ Antioquia Proceso continuo para la elaboracion de nanoparticulas y nanoparticulas obtenidas mediante dicho proceso
KR20200051841A (ko) 2011-04-28 2020-05-13 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
CN104168884A (zh) 2011-11-01 2014-11-26 细胞基因公司 使用胞苷类似物的口服制剂治疗癌症的方法
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
WO2013084207A1 (pt) 2011-12-07 2013-06-13 Universidade Do Minho Formulações micelares proteicas e respectivo método de produção
RU2499991C2 (ru) * 2011-12-14 2013-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северный государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ дифференциальной диагностики типа гепаторенального синдрома алкогольного генеза
DK2790675T3 (da) 2011-12-14 2019-09-09 Abraxis Bioscience Llc Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
BR112015001838B1 (pt) 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
RU2674249C2 (ru) 2012-11-05 2018-12-06 НэнтБайо, Инк. Замещенные производные индол-5-ола и их терапевтическое применение
WO2014071298A1 (en) 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
WO2014078435A1 (en) * 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
JP5999765B2 (ja) * 2012-12-07 2016-09-28 バイオアバイラビリティ，インク． 栄養学的に使用するための高濃度自己マイクロエマルジョン化コエンザイムｑ１０調製物
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
MX2015010312A (es) 2013-02-11 2015-11-18 Abraxis Bioscience Llc Metodos para tratamiento del melanoma.
ITBN20130001A1 (it) * 2013-02-19 2014-08-20 Prodal S C A R L Particelle biopolimeriche sub-micrometriche per la veicolazione di composti attivi in campo alimentare, farmaceutico e cosmetico e procedimento per la loro preparazioneparticelle biopolimeriche sub-micrometriche per la veicolazione di composti attivi
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
KR20150126671A (ko) 2013-03-13 2015-11-12 아브락시스 바이오사이언스, 엘엘씨 소아 고형 종양의 치료 방법
US9962373B2 (en) 2013-03-14 2018-05-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
US20150367073A1 (en) 2013-03-15 2015-12-24 Windgap Medical, Llc Portable Drug Mixing and Delivery Device and Associated Methods
US10569017B2 (en) 2013-03-15 2020-02-25 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
JP6560187B2 (ja) 2013-03-15 2019-08-14 ウインドギャップ メディカル インコーポレイテッド 携帯型薬剤混合及び送達システム並びに方法
RU2017141536A (ru) 2013-03-15 2019-02-13 Нэнтбайосайенс, Инк. Замещенные производные индол-5-ола и их терапевтические применения
US9907910B2 (en) 2013-03-15 2018-03-06 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
KR101329646B1 (ko) 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
CN103393632B (zh) * 2013-07-26 2015-05-13 齐鲁制药(海南)有限公司 一种卡巴他赛药物组合物及其制备方法
CN104368007A (zh) * 2013-08-12 2015-02-25 于湛 可注射蛋白基花样结构载药微纳材料与内耳跨膜给药缓释制剂及其制备方法
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
CN104758942A (zh) * 2014-01-02 2015-07-08 国家纳米科学中心 基于蛋白质的药理活性物质组合物及其制备方法和应用
CN103705469B (zh) * 2014-01-03 2016-01-20 中国医学科学院药用植物研究所 一种和厚朴酚纳米粒及其制备方法
JP6280996B2 (ja) * 2014-02-14 2018-02-14 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 治療剤の放出を伴う急速分解性塞栓粒子および同塞栓粒子を含む医療用組成物
CN103861115B (zh) * 2014-03-18 2017-04-19 常州市第一人民医院 一种血红蛋白纳米粒及其制备方法
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法
US11116903B2 (en) 2014-08-18 2021-09-14 Windgap Medical, Inc Compression seal for use with a liquid component storage vial of an auto-injector
JP6655845B2 (ja) * 2014-12-05 2020-02-26 国立大学法人神戸大学 ｉｎ ｖｉｖｏステルス性ナノ粒子
CN105727303B (zh) * 2014-12-12 2019-06-28 四川科伦药物研究院有限公司 一种高载卡巴他赛药物的白蛋白组合物及其制剂和制备方法
CN104490797A (zh) * 2014-12-22 2015-04-08 深圳海王药业有限公司 一种多相稳定的白蛋白结合型卡巴他塞
WO2016137506A1 (en) 2015-02-27 2016-09-01 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
US10527604B1 (en) * 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN106137969B (zh) * 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
JP6606274B2 (ja) 2015-04-15 2019-11-13 ウィンドギャップ メディカル， インコーポレイテッド オートインジェクタアセンブリに使用される取り外し可能作動用キャップ
JP6983660B2 (ja) * 2015-05-08 2021-12-17 スペクトラル プラットフォームス インコーポレイテッド アルブミンに基づく非共有結合性複合体およびその使用方法
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
EP3313447A2 (en) 2015-06-25 2018-05-02 Sanford Burnham Prebys Medical Discovery Institute Compositions for delivery to and treatment of atherosclerotic plaques
SG10202107198SA (en) 2015-06-29 2021-08-30 Abraxis Bioscience Llc Methods of treating epithelioid cell tumors
AU2016306797B2 (en) 2015-08-13 2021-05-20 Windgap Medical, Inc Mixing and injection device with sterility features
CN105055341A (zh) * 2015-08-13 2015-11-18 黑龙江泰华源生物技术有限责任公司 一种紫杉醇白蛋白结合型冻干制剂及其制备方法
CN105816885A (zh) * 2016-04-15 2016-08-03 北京大学 一种药物白蛋白纳米粒的制备及其应用方法
JP7094226B2 (ja) * 2016-04-29 2022-07-01 ルスロ・ベー・フェー 医薬品有効成分用のタンパク質をベースにした添加物
BE1023653B1 (nl) * 2016-04-29 2017-06-07 Rousselot B.V. Eiwit gebaseerd excipient voor actieve farmaceutische stoffen
CN105944109B (zh) * 2016-05-03 2019-06-11 四川大学 一种肾小球靶向的蛋白纳米颗粒药物组合物及其用途
CN106310221B (zh) * 2016-08-25 2019-11-22 齐鲁制药有限公司 一种含有卡非佐米的药物组合物及其制备方法
WO2018048958A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
JP2019533665A (ja) * 2016-10-10 2019-11-21 アブラクシス バイオサイエンス， エルエルシー ナノ粒子製剤ならびにその作製方法および使用方法
PL3548001T3 (pl) * 2016-11-30 2022-07-11 Dukebox Sp. Z O.O. Sposób wytwarzania roztworu nanocząstek kwasu acetylosalicylowego albo diosminy albo drotaweryny
EP3602065A4 (en) 2017-03-20 2020-12-23 Spectral Platforms, Inc. SPECTROSCOPIC METHODS OF DETECTION AND CHARACTERIZATION OF MICROORGANISMS
CN110753541A (zh) * 2017-04-24 2020-02-04 Zy治疗公司 用于体内递送的药物组合物、基本上不溶于水的药理学活性剂的制备方法
CN107412783B (zh) * 2017-04-28 2020-09-22 中国人民解放军军事医学科学院毒物药物研究所 一种包裹有难溶于水药物的蛋白质颗粒的制备方法
WO2018204392A1 (en) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
US10738033B2 (en) 2017-05-31 2020-08-11 Nantbio, Inc. Trk inhibition
US10800760B2 (en) 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
WO2019016692A1 (en) * 2017-07-21 2019-01-24 Emcure Pharmaceuticals Limited PARTICLE SIZE STABILIZATION OF PROTEIN-RELATED PARTICLES AND RELATED METHODS
CN107412172A (zh) * 2017-08-04 2017-12-01 南京拉克森生物医药科技有限公司 一种紫杉醇白蛋白纳米混悬剂冻干粉及其制备工艺
AU2018321260A1 (en) * 2017-08-25 2020-03-05 Y. Joseph Mo Compositions and methods of delivery of pharmacological agents
CN111918652A (zh) 2017-11-06 2020-11-10 拉普特医疗公司 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂
JP2021528362A (ja) 2018-03-20 2021-10-21 アブラクシス バイオサイエンス， エルエルシー ｍＴＯＲ阻害剤およびアルブミンのナノ粒子の投与を介して中枢神経系障害を処置する方法
CN108524452A (zh) * 2018-05-08 2018-09-14 辽宁大学 一种紫杉醇白蛋白纳米粒的制备方法和应用
AU2019274516A1 (en) 2018-05-22 2020-12-17 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
CN113905722A (zh) * 2019-01-22 2022-01-07 锐创生物医药(香港)有限公司 白蛋白纳米颗粒、其制备方法和用途
EP3921329A1 (en) 2019-02-04 2021-12-15 University of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
US20220218789A1 (en) 2019-05-10 2022-07-14 Nant Holdings Ip, Llc Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
CN115003284A (zh) 2019-10-28 2022-09-02 阿布拉科斯生物科学有限公司 白蛋白和雷帕霉素的药物组合物
US11318189B1 (en) 2020-05-13 2022-05-03 Nantcell, Inc. IL-15 agonist drug combinations for immune therapy
CN114681408B (zh) * 2020-12-26 2023-06-23 四川汇宇制药股份有限公司 白蛋白结合型紫杉醇纳米粒的制备方法
EP4036580A1 (en) * 2021-02-01 2022-08-03 Oxford University Innovation Limited Drug loaded cavitation agent
EP4035655A1 (en) * 2021-02-01 2022-08-03 Oxford University Innovation Limited Immune modulating particles
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
ATE34407T1 (de) * 1983-06-22 1988-06-15 Stolle Res & Dev Eingekapselte zellen, verfahren zu deren herstellung und ihre verwendung.
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
WO1988001506A1 (en) * 1986-08-28 1988-03-10 Thomas Ko Sai Ying Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
SE8704158L (sv) * 1987-10-26 1989-04-27 Carbomatrix Ab C O Ulf Schroed Mikrosfaerer, foerfarande foer framstaellning daerav och anvaendning daerav
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
NO176278C (no) * 1988-08-24 1995-03-08 Allied Colloids Ltd Fremgangsmåte for fremstilling av en partikkelformig blanding av aktiv bestanddel i et polymert materiale
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
CA2030551C (en) * 1989-05-01 1998-08-25 Wayne Gombotz Process for producing small particles of biologically active molecules
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.
CA2080014C (en) * 1990-04-17 2001-09-18 Stephen L. Kopolow Preparation of discrete microdroplets of an oil in water stabilized by in situ polymerization of a water-soluble vinyl monomer
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2683159B1 (fr) * 1991-10-31 1994-02-25 Coletica Procede de fabrication de nanocapsules a paroi a base de proteines reticulees; nanocapsules ainsi obtenues et compositions cosmetiques, pharmaceutiques et alimentaires en comportant application.
EP0646000A4 (en) * 1992-11-16 1997-05-02 Univ Mercer COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
DK0693924T4 (da) * 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
NZ335133A (en) 2000-12-22
EP1944019A2 (en) 2008-07-16
EP0961612A4 (en) 2005-12-21
EP0961612B1 (en) 2009-04-08
DE69739348D1 (de) 2009-05-20
EP1944019A3 (en) 2008-07-30
BRPI9715297B1 (pt) 2016-07-12
FR09C0050I1 (da) 2009-06-11
WO1998014174A1 (en) 1998-04-09
NO328689B1 (no) 2010-04-26
HK1024866A1 (en) 2000-10-27
AU718753B2 (en) 2000-04-20
CA2512487A1 (en) 1998-04-09
CN1515244B (zh) 2013-08-07
EP0961612B2 (en) 2012-08-01
JP2001501931A (ja) 2001-02-13
CA2267498C (en) 2007-05-08
CN1157185C (zh) 2004-07-14
AU4592997A (en) 1998-04-24
NL300417I1 (en) 2009-12-01
ATE427739T1 (de) 2009-04-15
BRPI9711856B1 (pt) 2016-07-12
CN1515244A (zh) 2004-07-28
NO991620L (no) 1999-06-01
BR9711856A (pt) 2001-11-06
JP2009185042A (ja) 2009-08-20
EP0961612A1 (en) 1999-12-08
EP2286798A1 (en) 2011-02-23
FR09C0050I2 (fr) 2012-06-22
DK0961612T4 (da) 2012-10-08
EP1944019B1 (en) 2016-09-07
ES2323559T3 (es) 2009-07-20
JP5117439B2 (ja) 2013-01-16
LU91613I2 (fr) 2009-12-07
BRPI9715297B8 (pt) 2021-05-25
DE122009000065I1 (de) 2010-01-07
JP4837809B2 (ja) 2011-12-14
CN1237901A (zh) 1999-12-08
PT961612E (pt) 2009-06-17
BRPI9711856B8 (pt) 2021-05-25
US5916596A (en) 1999-06-29
CA2267498A1 (en) 1998-04-09
ES2609853T3 (es) 2017-04-24
CA2512487C (en) 2012-05-29
NO991620D0 (no) 1999-04-06
ES2323559T5 (es) 2012-12-03

Similar Documents

Publication Publication Date Title
DK0961612T3 (da) Protein-stabiliserede-farmakologisk-aktive-midler og deres anvendelse
MX337149B (es) Nuevas formulaciones de agentes farmacologicos, metodos para su preparacion y metodos para el uso de los mismos.
EP2014286A3 (en) Cremophor free epothilone particles coated with protein for treating cancer
WO2000071079A3 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
JP5170934B2 (ja) 改良ｄｎａリポフェクションならびに／または徐放性プロドラッグおよび薬物療法のための試薬の合成と使用
BR0016012A (pt) Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração
ATE260651T1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
CY1110949T1 (el) Σταθεροποιημενες με πηκτωμα συνθεσεις νανοσωματιδιακων δραστικων παραγοντων
BR0014385A (pt) Composições quìmicas agrìcolas misturadas na embalagem tendo estabilidade melhorada
AU3468900A (en) Cyclodextrin polymers for use as drug carriers
DE69507339D1 (de) Polymer-mikrokugeln und verfahren zu deren herstellung
HK1075001A1 (en) Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
ATE124864T1 (de) Die wirkstoffabgabe steuerndes überzugsmaterial für lang wirksame formulierungen.
DE69929904D1 (de) Methode zur herstellung von beschichteten partikeln und diese enthaltende pharmazeutische formulierungen
TR200002772T2 (tr) Peroral etkin madde süspansiyonu
SG165156A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP0100303A2 (hu) Porózus hidroxiapatit részecskék mint gyógyszerhatóanyag hordozók
NO20011670L (no) Preparat for parenteral administrering av aktive forbindelser
MX9604984A (es) Composiciones farmaceuticas a base de derivados de la clase de los taxanos.
ES2133052A1 (es) Nuevas formulaciones farmaceuticas liquidas para la via oral.